Predictors of laryngeal complications in patients implanted with the cyberonics vagal nerve stimulator

Annals of Otology, Rhinology and Laryngology

Volumn 115, Issue 4, 2006, Pages 260-267

  Shaw, Gary Y ^a,b,d   Sechtem, Philip ^a   Searl, Jeff ^c   Dowdy, Emily S ^b  

^a Research Medical Center Brookside Campus   (United States)

^b KANSAS CITY UNIVERSITY OF MEDICINE AND BIOSCIENCES   (United States)

^c UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^d Lee's Summit ENT   (United States)

Author keywords

Vagal nerve stimulator; Voice complications

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; PHENYTOIN; PRIMIDONE; TOPIRAMATE; VALPROATE SEMISODIUM;

ADULT; AGED; ANTICONVULSANT THERAPY; ARTICLE; CLINICAL ARTICLE; DISABILITY; DISEASE SEVERITY; ELECTROMYOGRAPHY; EMOTION; ENDOTRACHEAL TUBE; FEMALE; HUMAN; IMPLANTATION; LARYNGOSCOPY; LARYNX DISORDER; MALE; NERVE STIMULATION; PHONATION; PRIORITY JOURNAL; QUESTIONNAIRE; SCORING SYSTEM; SEIZURE; SELF EVALUATION; SPEECH; TREATMENT OUTCOME; VAGUS NERVE STIMULATION; VIDEORECORDING; VOICE; VOICE HANDICAP INDEX;

EID: 33645995145     PISSN: 00034894     EISSN: None     Source Type: Journal    
DOI: 10.1177/000348940611500403     Document Type: Article

References (19)

1. Morris GL III, Mueller WM. Long-term treatment with vagus nerve stimulation in patients with refractory epilepsy. The Vagus Nerve Stimulation Study Group E01-E05. Neurology 1999;53:1731-5.
2. [Erratum in Neurology 2000;54:1712.]
3. Charous SJ, Kempster G, Manders E, Ristanovic R. The effect of vagal nerve stimulation on voice. Laryngoscope 2001; 111:2028-31.
4. Santos PM. Evaluation of laryngeal function after implantation of the vagus nerve stimulation device. Otolaryngol Head Neck Surg 2003;129:269-73.
5. Zalvan C, Sulica L, Wolf S, Cohen J, Gonzalez-Yanes O, Blitzer A. Laryngopharyngeal dysfunction from the implant vagal nerve stimulator. Laryngoscope 2003;113:221-5.
6. Shaffer MJ, Jackson CE, Szabo CA, Simpson CB. Vagal nerve stimulation: clinical and electrophysiological effects on vocal fold function. Ann Otol Rhinol Laryngol 2005;114:7-14.
7. Hirano M, Bless DM. Videostroboscopic examination of the larynx. San Diego, Calif: Singular Publishing Group, 1993.
8. Jacobson BH, Johnson A, Grywalski C, et al. The voice handicap index (VHI): development and validation. Am J Speech Lang Pathol 1997;6:66-70.
9. Koufman J, Walker F. Laryngeal electromyography in clinical practice: indications, technique, and interpretation. Phonoscope 1998;1:57-70.
10. Amar AP, Heck CN, Levy ML, et al. An institutional experience with cervical vagus nerve trunk stimulation for medically refractory epilepsy: rationale, technique, and outcome. Neurosurgery 1998;43:1265-80.
11. Deem JF. The voice evaluation. In: Deem JF, Miller L, eds. Manual of voice therapy. 2nd ed. Austin, Tex: Pro-Ed, 2000:41-50.
12. Siegal S, Castellan N. Nonparametric statistics for the behavioral sciences. 2nd ed. New York, NY: McGraw-Hill, 1988: 94-118.
13. Hauser WA. Incidence and prevalence. In: Engel J Jr, Pedley TA, eds. Epilepsy: a comprehensive textbook. Philadelphia, Pa: Lippincott-Raven, 1997:47-57.
14. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000;342:314-9.
15. Vagal nerve stimulation, an innovative therapy for depression, gets FDAapproval. Sydney, Australia: News-Medical Net, July 15, 2005.
16. Geraldini C, Faedda MT, Sideri G. Anticonvulsant therapy and its possible consequences on peripheral nervous system: a neurographic study. Epilepsia 1984;25:502-5.
17. So EL, Penry JK. Adverse effects of phenytoin on peripheral nerves and neuromuscular junction: a review. Epilepsia 1981;22:467-73.
18. Mochizuki Y, Suyehiro Y, Tanizawa A, Ohkubo H, Motomura T. Peripheral neuropathy in children on long-term phenytoin therapy. Brain Dev 1981;3:375-83.
19. Wheless JW, Maggio V. Vagus nerve stimulation therapy in patients younger than 18 years. Neurology 2002;59(suppl 4): S21-S25.